Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Facial Bone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Facial Bone. Displaying page 1 of 1.
    EudraCT Number: 2006-000428-15 Sponsor Protocol Number: STEROID Start Date*: 2006-04-19
    Sponsor Name:HANNA THORÉN
    Full Title: INFLUENCE OF DEKSAMETASONE ON POST-OPERATIVE RECOVERY AFTER OPERATIVE TREATMENT OF FACIAL FRACTURES
    Medical condition: FRACTURES OF THE FACIAL BONES
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001885-14 Sponsor Protocol Number: HN010/HTF-003 Start Date*: 2005-08-24
    Sponsor Name:Henogen s.a.
    Full Title: A phase II, randomised, double blind, matched pair, controlled study to assess the safety and efficacy of Henogen recombinant soluble human tissue factor (rshTF) on the mandible bone consolidation...
    Medical condition: Orthognathic surgery, cases of Bilateral Sagittal Split Osteotomy (B.S.S.O) of the mandible to achieve facial and occlusal balance. This could create bone gaps or continuity defects. These bone gap...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001167-75 Sponsor Protocol Number: FIBEA-04-EC-19-ALV Start Date*: 2019-09-09
    Sponsor Name:BTI I MAS D
    Full Title: Randomized Clinical Trial, conventional treatment-controlled, studying the efficacy of Plasma Rich in Growth Factor (PRGF®) in alveolar ridge preservation after simple exodontia in the anterior reg...
    Medical condition: Alveolar ridge preservation after exodontia of uniradiculate dental pience in the anterior region of maxilla
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004972-74 Sponsor Protocol Number: 20160227 Start Date*: 2020-09-15
    Sponsor Name:Amgen Inc.
    Full Title: An Open-label, Ascending Multiple dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents With Osteogenesis Imperfecta
    Medical condition: Osteogenesis imperfecta (OI) is a group of genetic skeletal disorders characterized by increased bone fragility, low bone mass , and increased bone turnover contributing to osteoporosis, fracture...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) GR (Completed) IT (Ongoing) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000184-40 Sponsor Protocol Number: 20130173 Start Date*: 2014-09-11
    Sponsor Name:Amgen, Inc.
    Full Title: Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta
    Medical condition: Osteogenesis Imperfecta
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) ES (Completed) Outside EU/EEA BG (Completed) PL (Prematurely Ended) BE (Completed) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003323-11 Sponsor Protocol Number: ITIBU001 Start Date*: 2014-10-01
    Sponsor Name:"Sapienza" University of Rome
    Full Title: RANDOMIZED CLINICAL TRIAL, PLACEBO-CONTROLLED, SPLIT-MOUTH, A DOUBLE-BLIND, FOR THE EVALUATION OF THE EFFECTIVENESS OF PREemptive ANALGESIA BY ADMINISTRATION OF IBUPROFEN 400MG, FOR THE CONTROL ...
    Medical condition: POST-OPERATIVE ACUTE PAIN (DAPO)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10017947 - Gastrointestinal disorders 10031009 Oral pain PT
    17.1 10017947 - Gastrointestinal disorders 10030973 Oral discomfort PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002278-30 Sponsor Protocol Number: APH-19 Start Date*: 2020-08-12
    Sponsor Name:Amryt Pharmaceuticals DAC
    Full Title: Phase III, single-arm, open-label, international, multi-centre study to evaluate the efficacy and safety of lomitapide in paediatric patients with Homozygous Familial Hypercholesterolaemia (HoFH) o...
    Medical condition: Homozygous familial hypercholesterolaemia (HoFH). A rare and life-threatening inherited disorder of lipid metabolism with an estimated prevalence of 1 per 160,000 to 300,000 in the European populat...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057100 Homozygous familial hypercholesterolaemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004766-34 Sponsor Protocol Number: CLCI699C2301 Start Date*: 2014-08-01
    Sponsor Name:NOVARTIS FARMA S.p.A.
    Full Title: A Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of...
    Medical condition: Cushing's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) DE (Completed) AT (Completed) ES (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003806-33 Sponsor Protocol Number: AEGR-733-020 Start Date*: 2016-06-30
    Sponsor Name:Aegerion Pharmaceuticals Inc.
    Full Title: A Phase 3, Single-arm, Open-label, International, Multi-center Study to Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients with Homozygous Familial Hypercholesterolemia on Stable ...
    Medical condition: Homozygous familial hypercholesterolemia (HoFH).
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10057080 Homozygous familial hypercholesterolemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GR (Not Authorised)
    Trial results: (No results available)
    EudraCT Number: 2016-000899-23 Sponsor Protocol Number: CORT125134-451 Start Date*: 2016-08-16
    Sponsor Name:Corcept Therapeutics Incorporated
    Full Title: Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing’s Syndrome
    Medical condition: Endogenous Cushing’s Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10011657 Cushings syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002193-31 Sponsor Protocol Number: CRN00808-05 Start Date*: 2020-02-19
    Sponsor Name:Crinetics Pharmaceuticals, Inc.
    Full Title: AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRN00808 IN SUBJECTS WITH ACROMEGALY (ACROBAT ADVANCE)
    Medical condition: Acromegaly is typically caused by a growth hormone (GH) secreting tumor in the pituitary. Excess GH secretion results in excess secretion of insulin-like growth factor-1 (IGF-1) from the liver, whi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) SK (Completed) GR (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003096-35 Sponsor Protocol Number: CORT125134-455 Start Date*: 2019-06-19
    Sponsor Name:Corcept Therapeutics Incorporated
    Full Title: Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant
    Medical condition: Endogenous Cushing syndrome
    Disease: Version SOC Term Classification Code Term Level
    24.0 10014698 - Endocrine disorders 10011657 Cushings syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BG (Ongoing) AT (Completed) PL (Ongoing) ES (Ongoing) DE (Completed) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004111-22 Sponsor Protocol Number: CSOM230B2305 Start Date*: 2007-01-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recu...
    Medical condition: Cushing’s disease is rare disease that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. The elevated ACTH secreted by these tumors stimulates the adrenal glands to pr...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011651 Cushing's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) BE (Completed) IT (Completed) FI (Completed) FR (Completed) DE (Completed) PT (Completed) GR (Completed) GB (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-004299-41 Sponsor Protocol Number: ERMES Start Date*: 2014-12-24
    Sponsor Name:Dipartimento di Scienze Mediche Oncologia Medica Policlinico Gemelli
    Full Title: ERbitux MEtastatic colorectal cancer Strategy Study: A phase III randomized two arm study with FOLFIRI + Cetuximab until disease progression compared to FOLFIRI + Cetuximab for 8 cycles followed by...
    Medical condition: Patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001936-11 Sponsor Protocol Number: 3074K4-3339-WW Start Date*: 2009-03-20
    Sponsor Name:Wyeth Pharmaceuticals Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Tigecycline Versus Clindamycin for the Treatment of Complicated Skin and Skin Structure Infections, Inc...
    Medical condition: Complicated skin and skin structure infection (cSSSI) with or without methicillin-resistant Staphylococcus aureus (MRSA)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040872 Skin infection LLT
    9.1 10066409 Staphylococcal skin infection LLT
    9.1 10066412 Staphylococcal aureus skin infection LLT
    9.1 10040872 Skin infection LLT
    9.1 10066409 Staphylococcal skin infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) GB (Completed) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2021-006794-37 Sponsor Protocol Number: VRDN-001-101 Start Date*: 2022-08-03
    Sponsor Name:Viridian Therapeutics, Inc.
    Full Title: A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in normal healthy volunteers (NHVs) and sub...
    Medical condition: Thyroid eye disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10015919 - Eye disorders 10084358 Thyroid eye disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Ongoing) IT (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:41:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA